Information Provided By: 
Fly News Breaks for June 12, 2017
NUVA
Jun 12, 2017 | 05:59 EDT
After traveling with management, Piper Jaffray analyst Matt O'Brien "strongly" recommends purchase of NuVasive and raised his price target for the shares to $90 from $80. NuVasive's Q2 "is shaping up well" and the programs its implementing "could redefine how companies operate in the spine market," O'Brien tells investors in a research note. He expects the company to continue taking domestic market share and keeps an Overweight rating on the stock.
News For NUVA From the Last 2 Days
There are no results for your query NUVA
